MAXCYTE INC (MXCT) Stock Fundamental Analysis

NASDAQ:MXCT • US57777K1060

0.7751 USD
-0.01 (-1.89%)
Last: Mar 3, 2026, 03:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall MXCT gets a fundamental rating of 3 out of 10. We evaluated MXCT against 57 industry peers in the Life Sciences Tools & Services industry. While MXCT has a great health rating, there are worries on its profitability. MXCT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • MXCT had negative earnings in the past year.
  • In the past year MXCT has reported a negative cash flow from operations.
  • MXCT had negative earnings in each of the past 5 years.
  • MXCT had a negative operating cash flow in each of the past 5 years.
MXCT Yearly Net Income VS EBIT VS OCF VS FCFMXCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • MXCT has a worse Return On Assets (-21.38%) than 68.42% of its industry peers.
  • Looking at the Return On Equity, with a value of -25.31%, MXCT is in line with its industry, outperforming 42.11% of the companies in the same industry.
Industry RankSector Rank
ROA -21.38%
ROE -25.31%
ROIC N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
MXCT Yearly ROA, ROE, ROICMXCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • MXCT has a better Gross Margin (79.97%) than 100.00% of its industry peers.
  • In the last couple of years the Gross Margin of MXCT has declined.
  • MXCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
MXCT Yearly Profit, Operating, Gross MarginsMXCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • MXCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MXCT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, MXCT has more shares outstanding
  • MXCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MXCT Yearly Shares OutstandingMXCT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MXCT Yearly Total Debt VS Total AssetsMXCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • MXCT has an Altman-Z score of -0.13. This is a bad value and indicates that MXCT is not financially healthy and even has some risk of bankruptcy.
  • MXCT has a worse Altman-Z score (-0.13) than 64.91% of its industry peers.
  • There is no outstanding debt for MXCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.13
ROIC/WACCN/A
WACC10.72%
MXCT Yearly LT Debt VS Equity VS FCFMXCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • A Current Ratio of 7.74 indicates that MXCT has no problem at all paying its short term obligations.
  • The Current ratio of MXCT (7.74) is better than 89.47% of its industry peers.
  • MXCT has a Quick Ratio of 7.27. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
  • MXCT has a Quick ratio of 7.27. This is amongst the best in the industry. MXCT outperforms 91.23% of its industry peers.
Industry RankSector Rank
Current Ratio 7.74
Quick Ratio 7.27
MXCT Yearly Current Assets VS Current LiabilitesMXCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • MXCT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.59%.
  • MXCT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.52%.
  • MXCT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.31% yearly.
EPS 1Y (TTM)-20.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)-24.52%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-16.35%

3.2 Future

  • Based on estimates for the next years, MXCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.36% on average per year.
  • MXCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.40% yearly.
EPS Next Y-4.09%
EPS Next 2Y13.36%
EPS Next 3Y12.98%
EPS Next 5Y11.36%
Revenue Next Year-7.52%
Revenue Next 2Y0.7%
Revenue Next 3Y7.45%
Revenue Next 5Y20.4%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MXCT Yearly Revenue VS EstimatesMXCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
MXCT Yearly EPS VS EstimatesMXCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • MXCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MXCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MXCT Price Earnings VS Forward Price EarningsMXCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MXCT Per share dataMXCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MXCT's earnings are expected to grow with 12.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.36%
EPS Next 3Y12.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MXCT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MAXCYTE INC

NASDAQ:MXCT (3/3/2026, 3:23:01 PM)

0.7751

-0.01 (-1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-12
Earnings (Next)03-24
Inst Owners70.4%
Inst Owner Change-6.81%
Ins Owners1.32%
Ins Owner Change0%
Market Cap82.68M
Revenue(TTM)34.42M
Net Income(TTM)-45.63M
Analysts83.08
Price Target5.75 (641.84%)
Short Float %5.1%
Short Ratio4.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.97%
Min EPS beat(2)-13.86%
Max EPS beat(2)19.79%
EPS beat(4)3
Avg EPS beat(4)8.05%
Min EPS beat(4)-13.86%
Max EPS beat(4)19.79%
EPS beat(8)7
Avg EPS beat(8)17.39%
EPS beat(12)9
Avg EPS beat(12)13.75%
EPS beat(16)13
Avg EPS beat(16)15.62%
Revenue beat(2)0
Avg Revenue beat(2)-16.24%
Min Revenue beat(2)-20.01%
Max Revenue beat(2)-12.47%
Revenue beat(4)2
Avg Revenue beat(4)-4.92%
Min Revenue beat(4)-20.01%
Max Revenue beat(4)7.51%
Revenue beat(8)6
Avg Revenue beat(8)10.53%
Revenue beat(12)7
Avg Revenue beat(12)4.03%
Revenue beat(16)11
Avg Revenue beat(16)5.63%
PT rev (1m)-11.07%
PT rev (3m)-11.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)6.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.08%
Revenue NY rev (1m)-1.07%
Revenue NY rev (3m)-3.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.4
P/FCF N/A
P/OCF N/A
P/B 0.46
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.32
BVpS1.69
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.38%
ROE -25.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.97%
FCFM N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.94%
Cap/Sales 4.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.74
Quick Ratio 7.27
Altman-Z -0.13
F-Score2
WACC10.72%
ROIC/WACCN/A
Cap/Depr(3y)270.47%
Cap/Depr(5y)255.66%
Cap/Sales(3y)18.33%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y-4.09%
EPS Next 2Y13.36%
EPS Next 3Y12.98%
EPS Next 5Y11.36%
Revenue 1Y (TTM)-24.52%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-16.35%
Revenue Next Year-7.52%
Revenue Next 2Y0.7%
Revenue Next 3Y7.45%
Revenue Next 5Y20.4%
EBIT growth 1Y-7.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.08%
EBIT Next 3Y14.64%
EBIT Next 5Y12.68%
FCF growth 1Y-22.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.54%
OCF growth 3YN/A
OCF growth 5YN/A

MAXCYTE INC / MXCT FAQ

What is the fundamental rating for MXCT stock?

ChartMill assigns a fundamental rating of 3 / 10 to MXCT.


Can you provide the valuation status for MAXCYTE INC?

ChartMill assigns a valuation rating of 0 / 10 to MAXCYTE INC (MXCT). This can be considered as Overvalued.


How profitable is MAXCYTE INC (MXCT) stock?

MAXCYTE INC (MXCT) has a profitability rating of 1 / 10.


What is the financial health of MAXCYTE INC (MXCT) stock?

The financial health rating of MAXCYTE INC (MXCT) is 7 / 10.